Treatment of acute nonlymphoblastic leukemia in adults with daunorubicin-DNA complex: a preliminary report.
Forty-four adult patients under 60 years of age with acute nonlymphoblastic leukemia were randomized for induction treatment with one of the following three regimens: R 1 = courses of daunorubicin on day 1 + ARA-C on days 1--5; R 2 = courses of daunorubicin on days 1 and 2 + ARA-C on days 4--8; R 3 = courses of daunorubicin-DNA complex on days 1--2 + ARA-C on days 4--8. Out of 14 patients, 9 went into remission on R 1, 6 out of 14 on R 2, and 8 out of 16 on R 3. The preliminary results suggest that daunorubicin-DNA complex has the same efficacy for inducing remission as daunorubicin alone, if the same time intervals and dosages are used.
D000208:Acute Disease; D004247:DNA / Q000009:adverse effects / Q000627:therapeutic use*; D003630:Daunorubicin / Q000009:adverse effects / Q000627:therapeutic use*; D005069:Evaluation Studies as Topic; D006801:Humans; D007938:Leukemia / Q000188:drug therapy*; D008875:Middle Aged; D013997:Time Factors
D004247:DNA; D003630:Daunorubicin